EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins

Vista sencilla de ítem
dc.contributor.authorRemón, Jordi
dc.contributor.authorHendriks, Lizza E.L
dc.contributor.authorCardona-Mendoza, Andrés Felipe
dc.contributor.orcidCardona-Mendoza, Andrés Felipe [0000-0002-6697-5471]
dc.date.accessioned2020-10-14T23:01:38Z
dc.date.available2020-10-14T23:01:38Z
dc.date.issued2020
dc.description.abstractenglishAlthough targeted therapy is standard of care in a large subset of oncogenic addicted non-small cell lung cancers (NSCLC), until recently, this therapeutic approach has not been feasible for all genomic alterations such as for those tumors harboring Epidermal Growth Factor Receptor (EGFR) exon 20 insertion (ex20ins) mutations. Despite being the third most common EGFR mutation, a limited efficacy of first- and second-generation EGFR tyrosine kinase inhibitors (TKI) exists. This is related to the heterogeneity at the molecular level in EGFR ex20ins mutation variants and the finding that this mutation promotes active kinase conformation but does not increase the affinity for EGFR TKI. As a result, the prognosis of this population is diminished. Therefore, chemotherapy remained the most suitable strategy in this subset of EGFR mutant NSCLC patients. Recently, new treatment strategies have been reported in this landscape, either with new EGFR TKI or bispecific antibodies, which may establish a new standard of care in the coming future for these patients. Future research should focus on elucidating the oncogenic degree of all EGFR ex20ins variants, the potential role of combination strategies either with chemotherapy or immune checkpoint inhibitors, and the most appropriate first-line treatment strategy in this subgroup. Finally, the knowledge of mechanisms of acquired resistance to these new agents upon progression is a priority for personalising treatment at that time. It is in this framework, that we provide a thorough overview on this subject.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1016/j.ctrv.2020.102105
dc.identifier.instnameinstname:Universidad El Bosquespa
dc.identifier.issn0305-7378
dc.identifier.reponamereponame:Repositorio Institucional Universidad El Bosquespa
dc.identifier.repourlrepourl:https://repositorio.unbosque.edu.co
dc.identifier.urihttps://hdl.handle.net/20.500.12495/4440
dc.language.isoeng
dc.publisherElsevierspa
dc.publisher.journalCancer treatment reviewsspa
dc.relation.ispartofseriesCancer treatment reviews, 0305-7378, Vol. 90, 2020spa
dc.relation.urihttps://www.sciencedirect.com/science/article/abs/pii/S0305737220301432
dc.rights.accessrightshttps://purl.org/coar/access_right/c_abf2
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.accessrightsAcceso abierto
dc.rights.creativecommons2020-11
dc.rights.localAcceso abiertospa
dc.subject.keywordsEGFR exon 20 insertionsspa
dc.subject.keywordsPoziotinibspa
dc.subject.keywordsTAK-788spa
dc.subject.keywordsAmivantamabspa
dc.subject.keywordsOsimertinibspa
dc.titleEGFR exon 20 insertions in advanced non-small cell lung cancer: A new history beginsspa
dc.title.translatedEGFR exon 20 insertions in advanced non-small cell lung cancer: A new history beginsspa
dc.type.coarhttps://purl.org/coar/resource_type/c_6501
dc.type.driverinfo:eu-repo/semantics/article
dc.type.hasversioninfo:eu-repo/semantics/publishedVersion
dc.type.localArtículo de revista

Archivos

Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
Jordi Remona, Lizza E.L.Hendriks_2020.pdf
Tamaño:
3.33 MB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos